Updated:
Viridian Therapeutics
Viridian Therapeutics is a biotech company led by Steve Mahoney, developing antibody treatments for autoimmune and rare diseases from Waltham,...
Viridian Therapeutics
Viridian Therapeutics is a biotech company founded by Steve Mahoney, who also serves as President and CEO. The firm develops antibody-based medicines for autoimmune and rare diseases, with a strategic focus on targets with established commercial precedent. Its initial programs target thyroid eye disease and FcRn-mediated conditions. The company's strategy centers on engineering differentiated therapeutic candidates that offer improved safety, tolerability, and convenience versus existing options. Viridian allocates R&D resources to high unmet needs, designing drugs intended to surpass standard-of-care within commercially validated disease areas. Its pipeline is built on proprietary antibody discovery and engineering capabilities. The firm operates from a headquarters in Waltham, Massachusetts and a second office in Boulder, Colorado. Viridian's executive team spans 12 officers including a Chief Medical Officer, Chief Commercial Officer, and Chief Financial Officer. The board includes directors from Fairmount Funds Management, Investors Management Corporation, and Agios Pharmaceuticals. The company maintains a clinical-stage pipeline with thyroid eye disease as its lead program. A distinguishing feature of Viridian's approach is its targeted drug development model. Rather than pursuing broad platform technologies, the firm methodically improves upon known mechanisms in commercially established indications. This structure allows Viridian to de-risk discovery while addressing specific patient populations with high unmet medical needs.
General information
Firm type
Asset Manager
Year founded
—
AUM
Undisclosed
Location
Region
North America
Country
United States
City
Waltham
Corporate office
221 Crescent Street, Suite 103A, Waltham, MA 02453, United States
Additional offices
6200 Lookout Road, Boulder, CO 80301, United States
Principals
Steve Mahoney
President and Chief Executive Officer
Tom Beetham
Chief Operating Officer
Shan Wu, Ph.D.
Chief Business Officer
Radhika Tripuraneni, M.D.
Chief Medical Officer
Tony Casciano
Chief Commercial Officer
Melissa Manno
Chief Human Resources Officer
Seth Harmon
Chief Financial Officer
Jennifer Tousignant
Chief Legal Officer
Kyle Haraldsen
Chief Technical Operations Officer
Diane Stroehmann
SVP, Regulatory Affairs
Christian Zdybowicz
SVP, Portfolio Strategy and Leadership
Kirk Bertelsen, Ph.D.
SVP, Head of Research
Sector focus
Frequently asked questions
Who runs investment decisions at Viridian Therapeutics?
Steve Mahoney, as President and CEO, leads the company according to the firm's website. The executive team includes a Chief Financial Officer, Seth Harmon, and a Chief Business Officer, Shan Wu. Board members include representatives from Fairmount Funds Management and Investors Management Corporation.
How does Viridian Therapeutics source its drug development programs?
Viridian leverages internal expertise in antibody discovery and engineering to create its pipeline. The firm focuses on well-validated immunology targets with established commercial precedent, such as thyroid eye disease and FcRn-mediated conditions. This approach reduces discovery risk by targeting mechanisms with known clinical utility.
What investment stages does Viridian Therapeutics typically target?
Viridian operates as a clinical-stage biotech company. Its lead program in thyroid eye disease is in clinical trials, and its pipeline includes both preclinical and development-stage candidates. The firm's business development strategy targets partnered or in-licensed assets that match its therapeutic focus.
Which sectors does Viridian Therapeutics focus on?
Viridian concentrates exclusively on autoimmune and rare diseases. Its core expertise lies in antibody discovery and engineering for inflammatory and immunological conditions. The firm does not pursue oncology, central nervous system disorders, or gene therapy.
Where does the underlying wealth come from for Viridian Therapeutics?
As a publicly traded biotechnology company, Viridian Therapeutics is funded by institutional and public equity investors. The firm's board includes representatives from Fairmount Funds Management, which holds a significant position as founding investor. Specific family office or individual wealth origins for its executive team or board members are not publicly disclosed.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: